Novo Nordisk
NVO
1,195 hedge funds and large institutions have $23.2B invested in Novo Nordisk in 2023 Q2 according to their latest regulatory filings, with 125 funds opening new positions, 444 increasing their positions, 394 reducing their positions, and 83 closing their positions.
70% more capital inflows, than outflows
Capital inflows: $1.74B | Capital outflows: $1.02B
51% more first-time investments, than exits
New positions opened: 125 | Existing positions closed: 83
13% more repeat investments, than reductions
Existing positions increased: 444 | Existing positions reduced: 394
5% more funds holding
Funds holding: 1,141 → 1,195 (+54)
9% more call options, than puts
Call options by funds: $486M | Put options by funds: $448M
0.22% more ownership
Funds ownership: 6.17% → 6.39% (+0.22%)
16% less funds holding in top 10
Funds holding in top 10: 56 → 47 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$190M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$124M |
| 3 |
Tiger Global Management
New York
|
+$104M |
| 4 |
Lazard Asset Management
New York
|
+$85.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$72.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$234M |
| 2 |
Jennison Associates
New York
|
-$106M |
| 3 |
Senator Investment Group
New York
|
-$67.6M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$42.1M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$41.7M |
NVO Hedge Fund Activity: Q2 2023 in Review
1,195 of the 6,386 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2023, worth a combined $23.2B — up 5% from $22.1B a quarter earlier.
Buyers outnumbered sellers: 125 funds opened new NVO positions and 83 closed out — a net gain of 42 holders — while 444 added to existing stakes and 394 trimmed.
The largest buyer was 1832 Asset Management, opening a new position worth an estimated $190M. The largest seller was Renaissance Technologies, cutting an estimated $234M.
- 1,195 institutional investors held Novo Nordisk (NVO) as of Q2 2023, up from 1,141 in Q1 2023.
- Funds reported $23.2B of Novo Nordisk stock for Q2 2023, up 5% quarter-over-quarter.
- 125 funds opened new Novo Nordisk positions in Q2 2023 and 83 closed out, a net change of +42 holders.
- The largest Novo Nordisk buyer in Q2 2023 was 1832 Asset Management, an estimated $190M added.
- The largest Novo Nordisk seller in Q2 2023 was Renaissance Technologies, an estimated $234M sold.
Based on aggregated 13F filings for Q2 2023.